Novantrone (mitoxandrone)
Approved
by the FDA in 2000, Novantrone®
(generic name: mitoxantrone) is prescribed to treat various types of cancer, leukemia,
and to reduce neurological
disability and the frequency of relapses in patients
with multiple
sclerosis (secondary progressive, progressive relapsing
and worsening relapsing-remitting). Novantone is not
indicated in the treatment of patients with primary
progressive multiple sclerosis.In 2005, the FDA issued a warning, notifying healthcare professionals of the risk of severe heart problems connected with the use of mitoxantrone. Mitoxantrone has been connected to fatal heart problems (including heart failure) and dangerous blood disorders which result in a bone marrow suppression and a restraint of the body's ability to fight infections. In effect, mitoxantrone is given to intentionally suppress the immune system to lessen its attack on the body. While this is usually an effective means of fighting certain diseases, it also poses great health risks.
More common side effects are:
• A blue-green color of urine for 24 hours after receiving Novantrone.
• Mild or moderate nausea.
• Menstrual irregularities in women.
• Hair loss that may be mild to moderate (hair will usually grow back after treatment is discontinued).
Possible, more sever side effects are:
• Fever
• Chills
• Sore throat or cough
• Sores on lips or in mouth
• Shortness of breath
• Stomach pain
• Vomiting
• Diarrhea
• Painful or difficult urination
• Uneven or rapid heartbeat
• Swollen feet or ankles
• Unusual bleeding or bruising
• Pain, swelling, redness or irritation at the injection site
If you believe your Novantrone use has put you or a loved one in danger, please fill out our Case Review Contact Form to the right on this page to find out what your case is worth.
Dangerous Drugs
News Articles
News Articles
North Carolina Case Claims Financial Calamity From Bayer Drug
5/2/08 - Triangle Business Journal
(read more..)
Panel May Issue Subpoenas Related to FDA Approval
on Antibiotic Drug Ketek
1/28/08 - FDA
(read more..)
Second Safety Warning on Fentanyl Skin Patch
12/21/07 - FDA
(read more..)
F.D.A. Investigates Quit-Smoking Drug
11/20/07 - Associated Press
(read
more..)
Merck to Pay $4.85 Billion To Settle Most Vioxx Cases
11/09/07 - AngelReyesBlog.com
(read
more..)
Cephalon Drug Is Tied to Several Deaths
9/14/07 - The Wall Street Journal
(read
more..)
$5.5 Million Award in First Federal Fentanyl (Duragesic) Pain Patch Trial
6/19/07 - Press Release
(read
more...)